

Clinical Trials Summary for out of hours Important Reference



Lancashire Teaching
Hospitals

NHS Foundation Trust

Acronym study title	DYNAMIC
Study Details	<p>Circulating tumour DNA guided adaptive Braf and Mek inhibitor therapy. Primary objective is to assess whether tumours respond to reintroduction of encorafenib and binimetinib following first “drug off” period – assessed by % decrease in TAB level (tumour activity and burden level)</p> <p>Patient treated until progression, unacceptable toxicity or withdrawal of consent by patient. Minimum follow up of 12 months for patients who do not experience disease progression</p>
Principal Investigator PI Sub PI's	<p>PI – Prof R Board</p> <p>Sub Investigator – Dr K Prasad</p>
Research Nurse Team	<p>Research Nurse – Carolyn Hatch</p> <p>CTSO – Bethany webster</p>
Drug therapy	<p>Patient planned to receive Encorafenib 450 mg OD + Binimetinib 45 mg BD, standardly a continuous treatment. The Dyanmic trial will randomise participants to receive the standard of care arm A or arm B an adaptive treatment schedule with 4 weeks of standard treatment followed by adaptive cycles based on ctDNA TAB levels (tumour activity and burden level)</p>
In the event that a patient calls this hotline for advise	<p>Advise Research team and Prof R Board of any hospital admissions so these can be reported to the Trial sponsor within 24 hours and protocol requirements followed.</p>